Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03587636 · ClinicalTrials.gov registry record · Phase 2

Liposome Bupivacaine Interscalene Total Shoulder

A Phase 2 study of Acute Pain, sponsored by University of Minnesota.

Completed
Registry status
Phase 2
Development phase
77
Enrollment target
1
Study location

NCT03587636 is a Phase 2 study of Acute Pain that has completed, run by University of Minnesota. The registered enrollment target is 77 participants, below the 266-participant average among 50 other Acute Pain trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03587636, a Phase 2 study of Acute Pain, has completed, sponsored by University of Minnesota.

COMPLETED
Registry status
Phase 2
Development phase
77 participants
Enrollment target
1
Study location

Study Summary

This is a randomized prospective outcomes study comparing two groups of patients. One group will receive liposomal bupivacaine plus bupivacaine and the other will receive bupivacaine alone in interscalene blocks when undergoing total shoulder arthroplasty. The purpose of the study is to determine if LB plus bupivacaine provides superior pain control compared to bupivacaine alone when injected in an interscalene block for patients undergoing total shoulder arthroplasty surgery.

Conditions Studied

Interventions

  • DRUG Bupivacaine
  • DRUG liposome bupivacaine

Study Locations (1)

Minnesota

  • University of Minnesota - Minneapolis

Trial Details

FieldValue
Enrollment Target 77 participants
Start Date 2018-09-17
Est. Completion 2021-03-17
Phase Phase 2

Sponsor

University of Minnesota

966 total trials

What the Registry Record Tells You About NCT03587636

The ClinicalTrials.gov registry entry for NCT03587636 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 266-participant average among 50 other Acute Pain trials with a reported enrollment target (71% lower). The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Pain appearing as the primary indexed condition, and to 2 interventions - of which Bupivacaine is the first listed.

NCT03587636 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT03587636 about?

NCT03587636 is a clinical study titled "Liposome Bupivacaine Interscalene Total Shoulder". This is a randomized prospective outcomes study comparing two groups of patients. One group will receive liposomal bupivacaine plus bupivacaine and the other will receive bupivacaine alone in interscalene blocks when undergoing total shoulder arthroplasty. The purpose of the study is to determine if...

What is the current status of trial NCT03587636?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2018-09-17. Estimated completion is 2021-03-17.

What conditions does trial NCT03587636 study?

This clinical trial studies the following conditions: Acute Pain.

What interventions are being tested in trial NCT03587636?

The interventions under investigation include: Bupivacaine (DRUG), liposome bupivacaine (DRUG).

Who is sponsoring clinical trial NCT03587636?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03587636 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.